A O'Shaughnessy - JoVE Visualize

Showing results (151-160 of 190) with videos related to

Pageof 19

Sort By:

Neurosurgical Focus|August 5, 2008

Maximizing the potential of minimally invasive spine surgery in complex spinal disordersPatrick C Hsieh, Tyler R Koski, Daniel M Sciubba, et al.

Blood|October 15, 1995

A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapyJ A O'Shaughnessy, D J Venzon, M Gossard, et al.

Blood|March 15, 1996

Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancerJ A O'Shaughnessy, A Tolcher, D Riseberg, et al.

BMC Medical Genomics|November 20, 2012

Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trialKui Shen, Yuan Qi, Nan Song, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996

Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patientsA W Tolcher, K H Cowan, M H Noone, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2006

Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancerJoanne L Blum, E Claire Dees, Aparna Chacko, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007

UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecanClinton F Stewart, John C Panetta, Melinda A O'Shaughnessy, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancerF A Holmes, J A O'Shaughnessy, S Vukelja, et al.

Marine Pollution Bulletin|June 25, 2022

Invasiveness risks of naked goby, Gobiosoma bosc, to North Sea transitional watersJennifer A Dodd, Gordon H Copp, Hannah J Tidbury, et al.

ESMO Open|June 14, 2025

Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: a United States Electronic Health Records database analysisP Tarantino, H S Rugo, G Curigliano, et al.

Pageof 19

Showing results (151-160 of 190) with videos related to

Sort By:

Pageof 19

Neurosurgical Focus|August 5, 2008

Maximizing the potential of minimally invasive spine surgery in complex spinal disordersPatrick C Hsieh, Tyler R Koski, Daniel M Sciubba, et al.

Blood|October 15, 1995

A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapyJ A O'Shaughnessy, D J Venzon, M Gossard, et al.

Blood|March 15, 1996

Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancerJ A O'Shaughnessy, A Tolcher, D Riseberg, et al.

BMC Medical Genomics|November 20, 2012

Cell line derived multi-gene predictor of pathologic response to neoadjuvant chemotherapy in breast cancer: a validation study on US Oncology 02-103 clinical trialKui Shen, Yuan Qi, Nan Song, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996

Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patientsA W Tolcher, K H Cowan, M H Noone, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2006

Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancerJoanne L Blum, E Claire Dees, Aparna Chacko, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007

UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecanClinton F Stewart, John C Panetta, Melinda A O'Shaughnessy, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2002

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancerF A Holmes, J A O'Shaughnessy, S Vukelja, et al.

Marine Pollution Bulletin|June 25, 2022

Invasiveness risks of naked goby, Gobiosoma bosc, to North Sea transitional watersJennifer A Dodd, Gordon H Copp, Hannah J Tidbury, et al.

ESMO Open|June 14, 2025

Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2- early breast cancer: a United States Electronic Health Records database analysisP Tarantino, H S Rugo, G Curigliano, et al.

Pageof 19